First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter baumannii.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 27540902.
- Also identified by DOI 10.3171/2016.6.JNS16352.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors report on the first case of the intraventricular administration of tigecycline described in the Western literature. A 22-year-old man developed cerebrospinal fluid infection from an extremely drug-resistant strain of Acinetobacter baumannii as a complication of endoscopic transsphenoidal surgery for the removal of a giant pituitary adenoma. The patient was safely and successfully treated with the prolonged intraventricular administration of tigecycline. Here, the authors provide the schedule details that can be invaluable in treating meningitis from extremely drug-resistant bacterial strains. Intraventricular tigecycline can be a valuable tool against multidrug-resistant central nervous system infections.
Medical subject headings
- Acinetobacter Infections
- Acinetobacter baumannii
- Anti-Bacterial Agents
- Meningitis, Bacterial
- Tigecycline